Evidence map›Paper›PMID 21969383›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2011

Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination.

Andrew G Schache, Triantafilos Liloglou, Janet M Risk, Anastasia Filia, Terence M Jones, Jon Sheard, Julia A Woolgar, Timothy R Helliwell, Asterios Triantafyllou, Max Robinson and 4 more

2 registry-linked trialsOpen access · greenAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 129 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 11 pooled it
25.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01706939 phase3active not recruitingnot on this mapstarted 2012, after this paper: background citation

The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer

TypeinterventionalSponsorIcahn School of Medicine at Mount SinaiRan2012 to 2035Enrolled23ConditionsSquamous Cell CarcinomasArmsReduced Dose Radiation, Standard Dose Radiation, Carboplatin
NCT02945631 naactive not recruitingnot on this mapstarted 2016, after this paper: background citation

Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer

TypeinterventionalSponsorIcahn School of Medicine at Mount SinaiRan2016 to 2027Enrolled43ConditionsLocally Advanced HPV Positive Oropharynx CancerArmsPTV56, PTV50.4
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 11 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2016
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Andrew G SchacheDepartment of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
Triantafilos Liloglou
Janet M Risk
Anastasia Filia
Terence M Jones
Jon Sheard
Julia A Woolgar
Timothy R Helliwell
Asterios Triantafyllou
Max Robinson
Philip Sloan
Colin Harvey-Woodworth
Daniel Sisson
Richard J Shaw
Newcastle University · GBUniversity of Liverpool · GB

Funding

Wellcome Trust 093893
6 · The paper itself

Abstract

purposeHuman papillomavirus-16 (HPV16) is the causative agent in a biologically distinct subset of oropharyngeal squamous cell carcinoma (OPSCC) with highly favorable prognosis. In clinical trials, HPV16 status is an essential inclusion or stratification parameter, highlighting the importance of accurate testing. EXPERIMENTAL

designFixed and fresh-frozen tissue from 108 OPSCC cases were subject to eight possible assay/assay combinations: p16 immunohistochemistry (p16 IHC); in situ hybridization for high-risk HPV (HR HPV ISH); quantitative PCR (qPCR) for both viral E6 RNA (RNA qPCR) and DNA (DNA qPCR); and combinations of the above.

resultsHPV16-positive OPSCC presented in younger patients (mean 7.5 years younger, P = 0.003) who smoked less than HPV-negative patients (P = 0.007). The proportion of HPV16-positive cases increased from 15% to 57% (P = 0.001) between 1988 and 2009. A combination of p16 IHC/DNA qPCR showed acceptable sensitivity (97%) and specificity (94%) compared with the RNA qPCR "gold standard", as well as being the best discriminator of favorable outcome (overall survival P = 0.002). p16 IHC/HR HPV ISH also had acceptable specificity (90%) but the substantial reduction in its sensitivity (88%) impacted upon its prognostic value (P = 0.02). p16 IHC, HR HPV ISH, or DNA qPCR was not sufficiently specific to recommend in clinical trials when used in isolation.

conclusionsCaution must be exercised in applying HPV16 diagnostic tests because of significant disparities in accuracy and prognostic value in previously published techniques.

Indexed as

Carcinoma, Squamous CellDNA, ViralFemaleHuman papillomavirus 16HumansImmunohistochemistryIn Situ HybridizationMaleMiddle AgedOropharyngeal NeoplasmsPolymerase Chain ReactionPrognosisSensitivity and SpecificityDNA, Viral

Identifiers

PMID21969383
PMCPMC3188400
OpenAlexW1996749665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.